Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

  • Technology appraisal guidance
  • TA524
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

April 2021: We removed recommendation 1.2 because it's no longer needed.

ISBN: 978-1-4731-2964-1